Psychosomatics
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Psychosomatics 47:62-67, February 2006
doi: 10.1176/appi.psy.47.1.62
© 2006 Academy of Psychosomatic Medicine
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Löwe, B.
* Articles by Göbel, C.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Löwe, B.
* Articles by Göbel, C.
Related Collections
* Depression
* Interviews
* Tests
* Antidepressants

Responsiveness of the PHQ-9 to Psychopharmacological Depression Treatment

Bernd Löwe, M.D., Ph.D., Irini Schenkel, M.S., Caroline Carney-Doebbeling, M.D., M.S., and Claus Göbel, M.D.

Received July 20, 2004; revised February 25, 2005; accepted April 6, 2005. From the Dept. of General Internal and Psychosomatic Medicine, Univ. of Heidelberg Medical Center, Heidelberg, Germany (BL); the Regenstrief Institute, Indiana Univ. School of Medicine, Indianapolis, IN, USA (BL, CCD); and Clinical Research, Pfizer GmbH, Karlsruhe, Germany (IS, CG). Address correspondence and reprint requests to Dr. Löwe, Dept. of General Internal and Psychosomatic Medicine, Heidelberg Univ. Medical Center, Im Neuenheimer Feld 410, D-69120, Heidelberg, Germany. e-mail: bernd.loewe{at}med.uni-heidelberg.de

This is the first study that investigates the responsiveness of the Patient Health Questionnaire-9 (PHQ-9), a standard 9-item self-report depression scale, to antidepressant medication. Authors analyzed data from 1,788 depressed outpatients (66.8% women; mean age, 50.3 years), participating in a prospective, open-label, non-interventional, observational study of sertraline. On the 0–27-point PHQ-9 scale, the total sample gained 10.3 points at 12 weeks, corresponding to a standardized effect size of –1.85. With reference to two independent criterion standards, the PHQ-9 change scores were considerably greater in therapy responders than in nonresponders. The PHQ-9 was equally responsive in men and women. Therefore, the PHQ-9 qualifies as a practical tool for gauging response to pharmacological treatment in depressed patients.




This article has been cited by other articles:


Home page
FocusHome page
L. J. Fochtmann, F. F. Duffy, J. C. West, R. Kunkle, and R. M. Plovnick
Performance in Practice: Sample Tools for the Care of Patients with Major Depressive Disorder
Focus, January 1, 2008; 6(1): 22 - 35.
[Abstract] [Full Text] [PDF]


Home page
PsychosomaticsHome page
N. Holzapfel, C. Zugck, T. Muller-Tasch, B. Lowe, B. Wild, D. Schellberg, M. Nelles, A. Remppis, H. Katus, W. Herzog, et al.
Routine Screening for Depression and Quality of Life in Outpatients With Congestive Heart Failure
Psychosomatics, April 1, 2007; 48(2): 112 - 116.
[Abstract] [Full Text] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 2006 Academy of Psychosomatic Medicine. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. Academy of Psychosomatic Medicine
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org